Insights Into Acute Myeloid Leukemia (AML) Ohio and Pennsylvania

Perspectives on management of newly diagnosed and relapsed/refractory AML

Northeast – September 1, 2020
Purchase Report

Faculty Chair

Courtney D. DiNardo, MD

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

Insights on the following AML therapies were obtained

  • azacitidine
  • clofarabine
  • cytarabine and daunorubicin (ie, 7+3)
  • decitabine
  • enasidenib
  • gemtuzumab ozogamicin
  • gilteritinib
  • glasdegib
  • liposomal daunorubicin and cytarabine
  • midostaurin
  • sorafenib
  • venetoclax

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • A moderated virtual roundtable discussion focusing on treatment of AML was held on September 1, 2020.
  • Disease state and data presentations were developed in conjunction with a medical expert from the University of Colorado
  • The group of advisors comprised community oncologists from the Ohio and Pennsylvania (USA)
  • Data collection was accomplished through use of audience response system questioning and in-depth moderated discussion

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.